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Introduction
Sialic acids (SAs), including a number of their derivatives,
are ubiquitous at the terminal positions of the oligosac-
charides of glycoproteins.1,2 Due to their acidic nature,
they impart a net negative charge to the cell surface and
are important in cell–cell or cell–matrix interaction.3,4
The transfer of SA from cystidine-5-monophospho-
N-acetylneuraminic acid (CMP-NeuAc) to the terminal
position of the carbohydrate group of glycoproteins and
glycolipids is catalyzed by a family of sialyltransferases
(STs).5 Many studies have demonstrated that altered
sialylation, which occurs during certain pathologic
processes, such as oncogenic transformation, tumor
metastases, and invasion, is associated with enhanced
ST activity.6–15 Many glycoproteins, glycolipids and
oligosaccharides contain SA, which may occur in a
variety of structures. A separate ST is responsible for
the attachment of the SA residue in each of these
structures. STs are classified into 4 major groups based
on the types of glycosidic linkage: α2,3Gal (ST3
Gal: ST3β-galactoside α2,3-sialyltransferase), α2,6Gal
(ST6Gal: ST6β-galactosamide α2,6-sialyltransferase),
α2,6GalNAc (ST6GalNAc: [α-N-acetyl-neuraminyl-
2,3-β-galactosyl-1,3]-N-acetylgalactosaminide α-2,6-
sialyltransferase), and α2,8Gal STs (ST8Sia: ST8
α-N-acetyl-neuraminide α2,8-sialyltransferase).16 SA
and their derivatives are ubiquitous at the terminal posi-
tions of oligosaccharides of glycoproteins and glycolipids
in tissues. They play important roles in a large variety of
biological processes such as cell–cell communication,
cell–matrix interaction, and the maintenance of serum
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glycoproteins in circulation. The expression of sialyl-
glycoconjugates changes during development, differen-
tiation and oncogenic transformation, tumor invasion
and metastasis. Similarly, in the early stage of pregnancy,
trophoblast cells have to undergo adhesion, invasion and
proliferation to develop a healthy placenta; the cytobio-
logic behavior is similar to tumor growth and invasion.
Preeclampsia is a common disease occurring in
pregnant women, with an incidence of 2–5%. The diag-
nosis of preeclampsia includes hypertension, protein-
uria, and general edema. Its correlation with maternal
mortality is followed by postpartum hemorrhage only.
So far, the etiology of preeclampsia is not clear, but the
possibility of it being the result of failed penetration or
communication between extravillous cytotrophoblastic
cells and the spiral artery of the uterus in the second
trimester (14–16 weeks of gestational age) has been
suggested.17 This inadequate trophoblast invasion
results in a defective blood exchange between the
uterus and placenta, and further contributes to the
compensatory elevation of maternal blood pressure.18,19
According to literature reviews, activities of either α2,6
or α2,3 STs have been found in placental tissue. 20,21
A study of the expression of these enzymes in the pla-
cental tissue of preeclampsia patients has never been
reported. Based on observations of tumor behavior, we
highly suspected that the expression of these enzymes
would be significantly decreased. Therefore, we used
semiquantitative reverse transcription-polymerase chain
reaction (SQ-RT-PCR) and real-time quantitative
reverse transcription-polymerase chain reaction (RTQ-
PCR) to compare the expression of α2,6-sialyltrans-
ferases I (ST6Gal I), which is the most important
enzyme during disease transformation such as onco-
genic transformation, in placental tissue from patients
with and without preeclampsia. At the same time, the
enzyme activity of ST6Gal I was also examined.
Methods
Tissue collection
This prospective study involved 20 patients with
preeclampsia, who underwent cesarean section for
obstetric reasons, and 20 healthy and matched preg-
nant women without preeclampsia, but who were also
undergoing cesarean section for obstetric reasons
between January and December 2003. Normal preg-
nancy was defined as a pregnancy in which the mother
had normal blood pressure (≤ 140/90 mmHg), no
proteinuria, and an absence of medical and obstetric
complications. Preeclampsia was defined as maternal
systolic blood pressure ≥ 140 mmHg and/or diastolic
blood pressure ≥ 90 mmHg on 2 occasions, separated
by 6 hours and proteinuria > 300 mg in a 24-hour
period. To make this study even more uniform and
consistent, the tissue was collected from women with
mild preeclampsia only. Cases of severe preeclampsia
were excluded from this study. Preeclampsia was con-
sidered severe if 1 or more of the following criteria
were present: maternal blood pressure ≥ 160/
110 mmHg on 2 separate readings at least 6 hours
apart; proteinuria > 3 + or > 5 g/24 hours after 
20 weeks of gestation; oliguria of less than 500 mL 
in 24 hours; cerebral or visual disturbances; and pul-
monary edema or cyanosis. Patient consent for the
collection of placental tissues was obtained from all
women, according to the guidelines of the Human
Ethics Committee in our institute. The placental tissues
were obtained during the cesarean section procedure.
Fetal membranes and maternal decidua were removed,
and villous tissue was cut into approximately 1-inch
cubes and washed extensively with saline in order to
remove the blood. The cubes were immediately frozen
at –70°C for subsequent enzyme activity and SQ-RT-
PCR and RTQ-PCR analyses.
SQ-RT-PCR
Tissue was snap-frozen in liquid nitrogen until RNA
extraction. Forty milligrams of tissue were powdered in
liquid nitrogen. The method of RNA extraction and
SQ-RT-PCR has been described in detail.13,14,22 Briefly,
RNA was extracted using a StrataPrep total RNA
Miniprep Kit (Stratagene, La Jolla, CA, USA). Reverse
transcription into cDNA was achieved by using the
SuperScriptTM Preamplification System for First Strand
cDNA Synthesis (Life Technologies, Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s
protocol, with oligo(deoxythymidine) as the initiation
primer in a final reaction volume of 20 μL. The syn-
thesized cDNA in 1 μL was subjected to PCR amplifi-
cation using 4 pairs of ST-specific primers, respectively,
and the β-actin-specific primers. Meanwhile, the ex-
tracted RNA from the individual sample was subjected
to the following PCR reaction as a negative control.
The condition used for the PCR was set up based
on the titration experiment conducted, which is sum-
marized in Table 1. The PCR mixture consisted of 0.1 U
Super-Therm DNA polymerase (JMR Holdings, 
St. Louis, MO, USA), 1×PCR buffer (JMR Holdings),
1.5 mM MgCl2, 320 nM dNTPs, 0.8–1.6 μL of 10 μM
ST primers, 0.8–1.6 μL of 10 μM β-actin primers,
1 μL of cDNA and extra-distilled water added to 50 μL
(Table 2). All PCR experiments were conducted in the
GeneAmp PCR system 2400 (Applied Biosystems,
Singapore).
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Reaction products obtained were electrophoresed
in 2% agarose containing ethidium bromide. Density
measurements were made using an Alpha-Imager
2000. The density of each ST band was compared with
that of β-actin, which was co-amplified within the same
tube, and the ratio (density units of ST band/density
units of β-actin) was calculated. The detection limit
was 1 ng of double-stranded DNA. The linear portion
of the assay ranged up to 25 ng. The ST mRNA expres-
sion of each sample was determined in at least 3 inde-
pendent experiments. Using β-actin as an internal
standard, the deviation between triplicate measure-
ments was on average 21%.
RTQ-PCR for ST6Gal I, ST6Gal I Y + Z form,
ST6Gal I H form, and ST6Gal I X form
The detailed procedure has been reported pre-
viously.22,23 Briefly, kinetic PCR was performed on a
LightCycler (RocheDiagnostics, Mannheim, Germany)
using SYBR green I as a double-strand DNA-specific
binding dye and continuous fluorescence monitor-
ing.24–27 The primers for quantitative RT-PCR of
ST6Gal I, Y + Z type transcript, H transcript, and X
transcript were the same as those used for SQ-RT-
PCR. The expression of mitochondrial ATP synthase 6
(mATPsy6)-housekeeping genes was used in the PCR
reaction as an internal control. The mATPsy6 coding
Table 1. Condition for semiquantitative reverse transcription-polymerase chain reaction (SQ-RT-PCR)
Program 6Gal-I 6Gal-I Y+Z type 6Gal-I H type 6Gal-I X type
1 94°C 1 min 94°C 2 min 94°C 2 min 94°C 2 min
2 65°C 50 sec 94°C 1 min 94°C 1 min 94°C 1 min
3 72°C 2 min 40 sec 59°C 30 sec 49°C 30 sec 63°C 30 sec
4 1–3 repeated 5 times 72°C 50 sec 72°C 50 sec 72°C 50 sec
5 94°C 50 sec
6 67°C 50 sec
7 72°C 2 min 40 sec 2–4 repeated 35 times 2–4 repeated 35 times 2–4 repeated 35 times
8 5–7 repeated 25 times
9 72°C 10 min 72°C 10 min 72°C 10 min 72°C 10 min
10 4°C 10 min 4°C 10 min 4°C 10 min 4°C 10 min
Table 2. Primers used for target genes
Target cDNA Acceptor specificity Primers PCR product size (bp)
ST6Gal I β-galactoside 6gl(f)-5′-TAT CGT AAG CTG CAC CCC AAT C-3′ 372
α2,6-sialyltransferase (GenBank accession no. X17247 1281-1302)
6gl(r)-5′-TTA GCA GTG AAT GGT CCG GAAG-3′
(GenBank accession no. X17247 1652-1631)
ST6Gal I β-galactoside Z01(f)-5′-AGT CCA GGG AGA AGT GGT GA-3′ 362
Y+Z form α2,6-sialyltransferase (GenBank accession no. X17247 148-167)
Z01(r)-5′-CCA CAC ACA GAT GAC TGC AA-3′
(GenBank accession no. X17247 509-490)
ST6Gal I β-galactoside H01(f)-5′-TGT CTC TTA TTT TTT GCC TT-3′ 218
H form α2,6-sialyltransferase (GenBank accession no. Z35760, nucleotides 422-441)
H01(r)-5′-GGT GTG AAT CATAAT GAA GA-3′
(GenBank accession no. X17247, nucleotides 443-424)
ST6Gal I β-galactoside X01(f)-5′-CTT CTC CCA TAC CTT GCT CTA CA-3′ 253
X form α2,6-sialyltransferase (GenBank accession no. NM_003032 55-77)
X01(r)-5′-GAA GAT GTG TTC AGG GAA GTC AC-3′
(GenBank accession no. X17247 428-406)
β-actin β-actin(f)-5′-GGC ATC GTG ATG GAC TCC G-3′ 613
(GenBank accession no. BC004251 448-466)
β-actin(r)-5′-GCT GGA AGG TGG ACA GCG-3′
(GenBank accession no. BC004251 1042-1060)
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region was amplified using the forward primer
mATPsy6-f 5′-CAGTGATTATAGGCTTTCGCTC-
TAA-3′ (GenBank accession no. AF368271, nucleo-
tide 335-359, Tm 56.4°C) and the reverse primer
mATPsy6-r 5′-GGCCAGGGCTATTGGTTGAA-3′
(GenBank accession no. AF 368271, nucleotide 471-
452, Tm 60.5°C). Amplification was carried out in 
a total volume of 20 μL containing 0.5 μM of each
primer, 4mM MgCl2, 2μL LightCycler-FastStart DNA
Master SYBR green 1, and 2 μL of 1:50 diluted cDNA
prepared as described above.
In all experiments, a negative control reaction was
performed by replacing the cDNA template with sterile
water, and positive controls were performed with the
CC7T cell line, a cell line that expresses ST6Gal I.
Sialyltransferase assay
The detailed procedure has been reported pre-
viously.14,28 Asialo-fetuin (acceptor for ST6Gal I) was
from Sigma (St. Louis, MO, USA). CMP-[14C]NeuAc
(100 nCi/μL) came from Amersham (Amersham
Pharmacia Biotech, UK). The enzyme assay method
was modified from Kurosawa’s original design29 and
has been described previously.14,28 To obtain the
quantitative data, experiments were reexamined under
the linear condition with time and enzyme concen-
tration (enzyme activity unit, nanomol sialic acid/mg
protein/hour).
Statistical analysis
Statistical analysis of data was done using the statistical
software SPSS, version 10.0 (SPSS Inc., Chicago, IL,
USA). The Mann-Whitney test was used to test dif-
ferences between the expression of a given ST and its
regulator in the placental tissues of patients with and
without preeclampsia. Probability values below 5%
were considered statistically significant.
Results
No different ST6Gal I mRNA expression in
placental tissues between normal controls and
preeclampsia patients
Expression of ST6Gal I and its promoters, such as H
form, Y + Z form, and X form mRNAs in the placental
tissues of pregnant women with preeclampsia (n = 20)
and those without preeclampsia (n = 20) were exam-
ined by RT-PCR with co-amplification of β-actin. The
RNA quality was assessed by running it on an agarose
gel, while viability of the RNA in each tissue sample
was confirmed by amplification of complementary
DNA for GAPDH. The standard deviation between
triplicate measurements was 21%. In Figure 1, exam-
ples of SQ-RT-PCR results of placental tissue samples
from women with or without preeclampsia can be 
seen. ST6Gal I mRNA expression failed to show signifi-
cant difference between preeclampsia placental tissue
and normal control placental tissue (1.09 ± 0.39 vs.
1.04 ± 0.42, p = 0.99). To further dissect the control-
led promoter for ST6Gal I expression, we studied the
H form, the Y + Z form, and the X form. The X form
was rarely detected in the placental tissues of pre-
eclampsia or normal control women; therefore, we
did not study its expression further. Consistent with
the lack of difference of ST6Gal I expression in the
placental tissues between normal control women and
preeclampsia women, expression of either the H form
or the Y + Z form failed to show a significant difference
in the studied cases (H form, p = 0.66; Y + Z form,
p=1). Figure 2 summarizes the data in this study. RTQ-
PCR further confirmed the above findings, which
showed no significant difference between the 2 groups
(data not shown).
Low ST6Gal I enzyme activity of placental 
tissues from normal controls and 
preeclampsia patients
Consistent with the results of studying the mRNA
expression of ST6Gal I from the placental tissue of
normal controls and preeclampsia patients, no differ-
ence in ST6Gal I enzyme activity was noted between
the placental tissue of the normal controls and that of
the preeclampsia patients, due to the very low enzyme
M 1 2 3
Y+Z form
A
B
C
Hepatic form
Coding region
4 5 6 7 8 9 10 11 12 13
Figure 1. Specificity of RT-PCR products (A = Y + Z promoter; B = H
promoter; C = α2,6-sialyltransferase I) in placental tissues of those
with and without preeclampsia were documented with high-resolution
gel electrophoresis (1.5% agarose gel) and resulted in a single
product with the desired length (362 bp for Y + Z form, 218 bp for
H form, 372 bp for ST6Gal I, 613 bp for β-actin). Lanes 1–5: nor-
mal control placental tissue. Lanes 6–12: preeclampsia placen-
tal tissue. Lane 13: CC7T cell line.
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activity of the ST6Gal I enzyme in the placental tissues
from both groups (data not shown).
Discussion
The current structure of antenatal care has been devel-
oped around detecting preeclampsia. The detection of
hypertension and proteinuria, the defining signs of this
syndrome, is the key aim of frequent surveillance in
pregnancy. Preeclampsia occurs in about 3% of pregnant
women and results in around 100,000 maternal deaths
per year worldwide.30 The fetus is also affected, directly
through placental insufficiency and indirectly through
iatrogenic delivery; this accounts for 25% of all infants
with a very low birth weight (< 1,500 g).30 Many bio-
chemical substances, principally of placental and endo-
thelial origin, increase in preeclampsia. However, their
predictive value in detecting susceptible women before
clinical presentation is poor.30 Therefore, since altered
sialylation plays an important role during development,
differentiation and oncogenic transformation, tumor
invasion and metastasis,31,32 and of most importance,
possibly in the early stage of pregnancy, trophoblast
cells have to undergo adhesion, invasion and prolifera-
tion to develop a healthy placenta, the cytobiologic
behavior is similar to tumor growth and invasion, so it
is rational to expect changes in sialylation in the placen-
tal tissues of women with preeclampsia. In our previous
studies,13,14,22,23 we found that changes in α2,6 sialyla-
tion occurred frequently in oncogenic transformation,
and were correlated with the invasive behavior of tumor.
In addition, elevation of ST6Gal activity has been
reported in human choriocarcinoma (the α2,6 ST
activity in JEG-3 and BeWo, 2 choriocarcinoma cancer
cell lines, increased to levels several times higher than
those in placenta).33 Competitive PCR analysis
showed that the expression levels of mRNA encoding
α2,6 ST increased significantly as a result of tumori-
genesis,33 and the inadequate invasion of cytotro-
phoblasts into the spiral vessels of the uterus was
suspected to contribute to the pathogenesis of pre-
eclampsia over the long term.18,19 The decreased
expression of highly invasive molecules such as ST6Gal
I could be expected in the placental tissues of women
with preeclampsia. However, the enzyme activity of
ST6Gal I was very low in the placental tissues from
both the normal controls and patients with preeclamp-
sia. The ST6Gal I enzyme activity in the placental tis-
sues of women with and without preeclampsia was
not statistically different. Consistent with enzyme
activity, ST6Gal I mRNA expression in placental tis-
sue from women with and without preeclampsia was
also not statistically different. To further dissect the
reality of ST6Gal I expression, we evaluated their con-
trol region-regulator parts, including the H form, the
Y + Z form, and the X form. Dall’Olio34 has reviewed
the biosynthesis and functional role of ST6Gal in detail.
Cell type-specific mRNA isoforms generated by cell
type-specific promoters have been identified in human
ST6Gal I.35 A short mRNA form (Form 1) has been
isolated from the liver.36–38 A large transcript (Form
3), containing 2 5′-untranslated exons (exon Y + Z),
has been isolated from several human cell types.36,38–40
A distinct transcript (Form 2) containing exon X, but
not exon Y+Z, has been isolated from human B cell
lymphoblastoma cell lines.41,42 The transcription of
mRNA species differing in the 5′-untranslated regions
allows the quantitative regulation of ST6Gal I expres-
sion, not only at the transcriptional level, but also at
the translational level.34 In fact, the hepatic transcript
shows a higher translational efficiency in vitro.43 Several
post-translational modifications affecting enzyme
activity have been described so far.36–39 These data
provide the picture of an enzyme encoded by a single
gene whose expression is precisely regulated in a tissue-
and stage-specific manner, owing to the existence of
multiple regulatory mechanisms.34 Consistent with
ST6Gal mRNA expression, no statistically significant
difference of regulators (H form, Y + Z form, and X
form) in the placental tissues of women with and with-
out preeclampsia was found.
Since we could not find any statistical difference in
either ST6Gal I mRNA expression, its regulator, or
ST6Gal I enzyme activity in the placental tissues of
women with and without preeclampsia, we supposed
that neither ST6Gal I mRNA expression nor enzyme
activity are involved in the pathogenesis of preeclampsia.
The possible alternative explanations may include: (1)
the timing of the study was not appropriate because
0
1
2
H
Normal
ST6Gal 1 Y+Z
PIH1.5
0.5
Figure 2. mRNA expression of the α2,6-sialyltransferase I, the H
form promoter, and the Y + Z form promoter in placental tissues
of those with and without preeclampsia. Data are presented as
mean±standard deviation. PIH=pregnancy-induced hypertension
(preeclampsia in this study).
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trophoblast invasion with forming uterine–placental
circulation is active during the first trimester or the
first half of pregnancy; the ST6Gal I activity, which
underlies the pathogenesis of preeclampsia, might be
more important at that time, while the mRNA expres-
sion and enzyme activity of ST6Gal I of the placenta
were studied at the end of gestation in this study,
resulting in the negative report; (2) ST6Gal I might
not be involved in the formation of uterine–placental
circulation; in contrast, 1 or more of the other STs,
such as ST6GalNAc I, II, III, IV, V and VI, ST3Gal I,
II, III, IV, V and VI, and ST8Sia I, II, III, IV, V and VI
might be involved in the pathogenesis of preeclamp-
sia. The other possibility is that there is a real absence
of sialylation change in the placental tissues of women
with preeclampsia. The tumor invasion process and
trophoblast implantation process might be different.
The aberrant behaviors in tumor cells (altered ST6Gal I
expression and enzyme activity) in malignant diseases,
including trophoblastic cancer cell lines (JEG-3 and
BeWo; 2 choriocarcinoma cell lines) may not occur in
trophoblast implantation for establishing the uterine–
placental circulation, because trophoblast implantation
is a sophisticatedly controlled invasive process. All the
above might have contributed to the negative result
in this study. We hope that a future study will be able to
expand on the other types of STs and study the sialyla-
tion of placental tissue to clarify the relationship
between ST and trophoblast implantation on the nor-
mal and abnormal pregnancy status.
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